XSTOSECARE
Market cap703mUSD
Dec 23, Last price
48.96SEK
1D
1.53%
1Q
14.02%
Jan 2017
887.10%
IPO
1,267.60%
Name
Swedencare AB (publ)
Chart & Performance
Profile
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff powder cat; ProDen PlaqueOff dental bones for dogs; ProDen PlaqueOff mini dental care bones, a chewy bone for smaller dogs; and ProDen PlaqueOff soft chews for dogs and cats. The company also provides dietary supplements for cats, dogs, and horses under the NutriScience brand, such as Glucosamine and Stomax used to renew joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid for joints and mobility; KalmAid, which helps to calm nervous dogs; and OmegaAid and RevitalAid, a feed supplement used for healthy skin and coat. In addition, it develops and manufactures equine supplements, including Gastrocare used to relieve gastric pain and improve appetite; Equine Gold, which helps horse to thrive; ArthriAid used to aid horse's own natural manufacture of cartilage; and AnxiKalm, a supplement to calm excitable horses. Further, the company provides ProDen PlaqueOff teeth and gums, a natural food supplement to enhance dental hygiene and prevent tartar buildup for human. It distributes its products through pharmacies, veterinary clinics, pet shops, animal hospital, and online. Swedencare AB (publ) was incorporated in 1993 and is headquartered in Malmö, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 2,338,300 27.81% | 1,829,457 137.46% | 770,441 221.09% | |||||||
Cost of revenue | 1,062,100 | 826,630 | 543,857 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 1,276,200 | 1,002,827 | 226,584 | |||||||
NOPBT Margin | 54.58% | 54.82% | 29.41% | |||||||
Operating Taxes | 22,500 | (14,362) | 2,279 | |||||||
Tax Rate | 1.76% | 1.01% | ||||||||
NOPAT | 1,253,700 | 1,017,189 | 224,305 | |||||||
Net income | 58,600 -37.99% | 94,500 73.01% | 54,622 12.55% | |||||||
Dividends | (34,900) | (31,622) | (16,944) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 3,551,124 | 1,149,307 | ||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 37,800 | 39,840 | 17,814 | |||||||
Long-term debt | 1,838,200 | 2,127,728 | 808,282 | |||||||
Deferred revenue | (4,188) | 616,970 | ||||||||
Other long-term liabilities | 9,800 | 4,188 | (616,970) | |||||||
Net debt | 1,614,600 | 1,921,441 | 689,737 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 444,000 | 260,202 | 125,846 | |||||||
CAPEX | (33,900) | (74,690) | (27,782) | |||||||
Cash from investing activities | (176,400) | (4,666,252) | (1,868,745) | |||||||
Cash from financing activities | (271,600) | 4,494,555 | 1,587,849 | |||||||
FCF | 1,237,315 | 482,933 | (165,491) | |||||||
Balance | ||||||||||
Cash | 237,300 | 245,068 | 136,086 | |||||||
Long term investments | 24,100 | 1,059 | 273 | |||||||
Excess cash | 144,485 | 154,654 | 97,837 | |||||||
Stockholders' equity | 997,200 | 1,454,366 | 278,077 | |||||||
Invested Capital | 8,730,715 | 9,149,899 | 3,019,530 | |||||||
ROIC | 14.02% | 16.72% | 11.15% | |||||||
ROCE | 13.78% | 10.37% | 6.76% | |||||||
EV | ||||||||||
Common stock shares outstanding | 158,732 | 155,346 | 111,951 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 1,586,000 | 1,272,079 | 299,526 | |||||||
EV/EBITDA | ||||||||||
Interest | 93,400 | 40,527 | 7,654 | |||||||
Interest/NOPBT | 7.32% | 4.04% | 3.38% |